Tag
A multidisciplinary consensus provides practical, trial-design focused recommendations for testing systemic therapies around surgery or combined with locoregional treatment in hepatocellular carcinoma, emphasizing patient selection, endpoin
A clear, practice-focused summary of the 2026 ASCO living guideline on systemic treatment of metastatic castration‑resistant prostate cancer, emphasizing biomarker-driven choices, sequencing, and new options such as 177Lu‑PSMA and PARP inhi
Software-assisted response evaluation at six months reliably predicts survival outcomes in chronic graft-versus-host disease, offering a promising tool to guide treatment decisions and improve patient prognosis.
This article reviews evolving therapeutic sequences in advanced hepatocellular carcinoma, highlighting the integration of immune-based combinations, tyrosine kinase inhibitors, liver function preservation, and the emerging multidimensional
A Medicare-based study found the Oncology Care Model did not increase systemic therapy starts for newly diagnosed cancer and was linked to less treatment initiation and lower spending in poor-prognosis cancer.
A matched difference-in-differences study found that the Oncology Care Model did not increase systemic therapy initiation overall and was associated with lower treatment initiation and lower spending in poor-prognosis cancers.
